Yesterday, 8:19 AM
- SciClone Pharmaceuticals (NASDAQ:SCLN) announces two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China. The first patient has been treated in the Phase 3 trial of ZADAXIN in sepsis, a life-threatening infectious disease, for which the drug has previously demonstrated therapeutic benefit in a Phase 2 study. The goal of the SciClone-sponsored Phase 3 trial in sepsis is to build on positive data from a smaller, previously conducted trial which showed a survival advantage for sepsis patients treated with ZADAXIN.
- In addition, the first patient has been treated in the Phase 1 trial of PT-112, a multi-targeted platinum-pyrophosphate anticancer agent being developed for patients with advanced solid tumors. PT-112 is a key early-stage asset supporting SciClone's strategy to expand its oncology portfolio and drive long-term growth.
- SciClone obtained the development and commercialization rights to PT-112 from Phosplatin Therapeutics for Greater China and Vietnam, along with option rights in South Korea and Taiwan.
Mon, Sep. 12, 1:04 PM
- SciClone Pharmaceuticals (SCLN +0.9%) and Soligenix (OTCQB:SNGX -1.6%) enter into a licensing agreement granting SciClone the exclusive right to develop and commercialize dusquetide (SGX942) for the treatment of oral mucositis (OM) in patients with head and neck cancer in China, Taiwan, South Korea and Vietnam.
- Under the terms of the agreement, SciClone will make an upfront equity investment in Soligenix for $3M by buying 3,359,412 shares of common stock at $0.893. It will be responsible for all development, product registration and commercialization in the Territory. Soligenix will earn royalties on net sales and will supply the product to SciClone on a "cost-plus" basis.
- The deal builds on an earlier collaboration under which SciClone granted access to its OM data library in exchange for certain rights to SGX942 in the Greater China market.
- Dusquetide is a member of a class of peptides called an innate defense regulator (IDR) which has no direct antibiotic activity but modulates host responses, increasing survival and accelerating the resolution of tissue damage following exposure to pathogens.
- OM usually occurs in the mouth of patents undergoing anticancer treatments. Almost all head and neck cancer patients receiving chemo develop OM.
Tue, Aug. 9, 4:38 PM
Tue, Jul. 19, 12:46 PM
Tue, Jul. 19, 11:32 AM
- Micro cap SciClone Pharmaceuticals (SCLN -19.4%) slumps on more than 50% higher volume in response to its announcement that is no longer in active discussions with potential acquirers and it intends, at least for now, to remain an independent company.
- Based on a strategic review, the firm approached a number of potential suitors about a possible merger but failed to generate any interest in a transaction that would boost shareholder value.
- The company expects to generate $158M - 163M in revenues this calendar year. Non-GAAP EPS should be $0.70 - 0.74. Q2 results will be released on August 9.
Tue, Jul. 19, 11:02 AM
Fri, Jun. 17, 5:34 PM
Tue, May 10, 6:03 AM
Thu, Mar. 10, 4:15 PM
- SciClone Pharmaceuticals (NASDAQ:SCLN): Q4 EPS of $0.30
- Revenue of $42.9M (+3.6% Y/Y)
Wed, Mar. 9, 5:35 PM
Thu, Feb. 4, 5:39 PM
Mon, Jan. 11, 11:30 AM
- On a preliminary basis, SciClone Pharmaceuticals (SCLN +0.4%) expects revenues for 2015 to come in at $157M - 158M, at the high end of its guidance of $153M - 158M. It also expects to achieve its non-GAAP EPS target of $0.93 - 0.97.
- 2016 guidance will be released when final 2015 results are reported in March.
Dec. 21, 2015, 9:08 AM
- No doubt incentivized by recent clinical trial success, SciClone Pharmaceuticals (NASDAQ:SCLN) announces plans to develop and register Soligenix's (OTCQB:SNGX) SGX942 in greater China for the treatment of oral mucositis (OM) in patients with head and neck cancer.
- SciClone's decision is pursuant to its April 2013 collaboration deal with Soligenix that gave it commercialization rights to SGX942 in China, Hong Kong and Macau in exchange for providing Soligenix access to its oral mucositis clinical and regulatory data library, which SciClone built while it was developing its own candidate for OM, SCV-07, abandoned in 2012.
- Specific terms of the partnership are not disclosed.
- SGX942 is a synthetic peptide called an innate defense regulator that modulates the body's reaction to injury and infection.
- Previously: Soligenix's candidate for oral mucositis shows encouraging results in mid-stage study (Dec. 16)
Nov. 10, 2015, 12:48 PM
Nov. 10, 2015, 9:13 AM
Nov. 9, 2015, 5:40 PM